This was the stock's third consecutive day of gains.

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...

Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...

Q4 2024 Earnings Call Feb 13, 2025, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up ...

Zoetis has been granted a conditional license from the USDA for its avian flu vaccine. Since February 2022, more than 150 ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading ...

The U.S. Department of Agriculture (USDA) has granted conditional approval for a new bird flu vaccine for poultry.Thi ...